Renz C L, Laroche D, Thurn J D, Finn H A, Lynch J P, Thisted R, Moss J
Department of Anesthesia and Critical Care, The University of Chicago, Illinois, USA.
Anesthesiology. 1998 Sep;89(3):620-5. doi: 10.1097/00000542-199809000-00010.
Anaphylaxis, mediated by immunoglobulin E, may be clinically indistinguishable but is mechanistically different than chemically mediated anaphylactoid reactions induced by drugs such as morphine, curare, and vancomycin. A test to distinguish anaphylactic from anaphylactoid reactions would clarify therapeutic and medicolegal issues. Tryptase levels identify anaphylactic reactions but have not been evaluated in vivo during anaphylactoid reactions. A prospective, randomized, double-blinded, placebo-controlled trial of antihistamine chemoprophylaxis for rapid vancomycin infusion was performed, and plasma tryptase was measured using a new immunoassay. Histamine release was established by measurement of plasma histamine and the ability of prophylactic H1 and H2 antagonists to prevent common histamine-associated side effects. Tryptase levels were compared with histamine levels and clinical symptoms.
Before elective arthroplasty, 40 patients received vancomycin infusion (1 g over 10 min) and pretreatment with either antihistamines (1 mg/kg diphenhydramine and 4 mg/kg cimetidine) or placebo. Changes in tryptase (at peak histamine and 10 min after vancomycin infusion), histamine levels, and histamine-mediated symptoms were assessed using Fisher's exact test, the Student's t test, or the paired t test, as appropriate. Logistic regression models were used to quantify the association of clinical symptoms with antihistamine treatment and serum levels.
Plasma tryptase levels were unchanged (99% CI, -0.5 to 1.6) independent of increased histamine levels, antihistamine pretreatment, clinical symptoms, or all of these. Histamine levels >1 ng/ml were significantly associated with hypotension, moderate-to-severe rash, and stopped infusion. Antihistamine pretreatment significantly decreased the incidence and severity of the reactions.
Plasma tryptase levels were not significantly elevated in confirmed anaphylactoid reactions, so they can be used to distinguish chemical from immunologic reactions.
由免疫球蛋白E介导的过敏反应在临床上可能难以区分,但在机制上与由吗啡、箭毒和万古霉素等药物引起的化学介导的类过敏反应不同。区分过敏反应和类过敏反应的检测方法将有助于阐明治疗和法医学问题。类胰蛋白酶水平可识别过敏反应,但尚未在类过敏反应期间进行体内评估。我们进行了一项前瞻性、随机、双盲、安慰剂对照试验,以研究抗组胺药预防快速输注万古霉素的效果,并使用一种新的免疫测定法测量血浆类胰蛋白酶。通过测量血浆组胺以及预防性H1和H2拮抗剂预防常见组胺相关副作用的能力来确定组胺释放情况。将类胰蛋白酶水平与组胺水平和临床症状进行比较。
在择期关节置换术前,40例患者接受万古霉素输注(1 g在10分钟内输注完毕),并预先使用抗组胺药(1 mg/kg苯海拉明和4 mg/kg西咪替丁)或安慰剂进行预处理。根据情况,使用Fisher精确检验、Student t检验或配对t检验评估类胰蛋白酶(在组胺峰值和万古霉素输注后10分钟时)、组胺水平和组胺介导的症状的变化。使用逻辑回归模型量化临床症状与抗组胺药治疗和血清水平之间的关联。
血浆类胰蛋白酶水平未发生变化(99%可信区间,-0.5至1.6),与组胺水平升高、抗组胺药预处理、临床症状或所有这些因素均无关。组胺水平>1 ng/ml与低血压、中重度皮疹和输注停止显著相关。抗组胺药预处理显著降低了反应的发生率和严重程度。
在确诊的类过敏反应中,血浆类胰蛋白酶水平未显著升高,因此可用于区分化学性反应和免疫性反应。